Huachuang Securities: In the first half of the year, batch release volumes of mainstream swine vaccines all declined year-on-year; in June, prices of veterinary drug active pharmaceutical ingredients continued to trade weakly.

Amid the sector's low beta, focus on the progress of high-potential individual products, as innovation remains the key to long-term success.

Zhitong FinanceJul 21 14:05

Keqian Biological (688526) Q1 2026 Earnings Commentary: Innovation-Driven Strategy Navigates Market Cycles; Pet Vaccine Initiatives Unlock New Growth Opportunities

Event: The company recently released its Q1 2026 report, recording revenue of RMB 228 million, a 7.20% year-over-year decrease; attributable net profit was RMB 79 million, down 26.79% year-over-year; and non-recurring

Pacific SecuritiesJun 12 00:00

Keqian Bio (688526.SH) 2025 Annual Dividend Distribution: RMB 0.64 per share

Gelonghui, May 19 — KEQIAN BIOLOGICAL CO., LTD. (SHA: 688526) announced its 2025 annual profit distribution implementation notice. The profit distribution is based on the company's total share capital of 466,128,056 shares prior to the implementation of the plan, with a cash dividend of RMB 0.64 per share (gross), amounting to a total cash dividend of RMB 298,321,955.84 (gross). The record date for this equity distribution is May 25, 2026, and the ex-dividend date is May 26, 2026.

Gelonghui FinanceMay 19 17:51

China Merchants Securities: Decline in pork prices weighs on profitability; leading feed enterprises shine

At the bottom of the cycle, it is recommended to seize the opportunity to enhance the intrinsic value of leading pig farming enterprises and expand the growth potential of leading feed enterprises through overseas expansion.

Zhitong FinanceMay 18 13:44

Company Q&A | Keqian Biology: The company's product, live Mycoplasma bovis vaccine (HB150 strain), has obtained the approval number.

Gelonghui, May 14th | An investor asked Keqian Biology on an interactive platform about the reasons for the delay in obtaining the production approval number for its Mycoplasma bovis vaccine. The investor also inquired whether Jin Yu Biology's first-mover advantage would impact the sales of Keqian Biology’s Mycoplasma bovis vaccine. Keqian Biology responded by stating that its product, the live Mycoplasma bovis vaccine (HB150 strain), has already obtained the approval number. For details regarding the product’s sales performance, please refer to the company’s periodic reports. The company will continue to enhance research and development efforts as well as marketing initiatives to drive performance growth and actively reward its broad base of investors.

Gelonghui FinanceMay 14 15:22

Huachuang Securities Downgrades Wuhan Keqian Biology to Add From Strong Buy; Price Target Is 17.60 Yuan

MT NewswiresMay 12 20:15 · Ratings